World Journal of Surgical Oncology最新文献

{"title":"PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails.","authors":"Jiashou Wang, Yun Xu, Bo Hong, Qingjian Hou, Wenying Chen, Wenxiong Zhang, Wen Zheng","doi":"10.1186/s12957-025-03877-0","DOIUrl":"10.1186/s12957-025-03877-0","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of PD-1/PD-L1 inhibitors plus chemotherapy (PIC) as a first-line treatment for advanced biliary tract cancer (BTC) remains controversial, given inconsistent findings regarding survival benefits and safety concerns. This meta-analysis systematically evaluates the safety and efficacy of PIC versus chemotherapy alone, aiming to provide more definitive guidance for BTC treatment decisions.</p><p><strong>Methods: </strong>To identify phase 3 randomized controlled trials (RCTs) comparing PIC with chemotherapy alone in patients with advanced BTC, a comprehensive literature search was conducted across six databases. Primary outcomes were overall survival (OS) and progression-free survival (PFS), while secondary outcomes included response rates and adverse events (AEs).</p><p><strong>Results: </strong>Two phase 3 RCTs (KEYNOTE-966 and TOPAZ-1) involving 1,754 patients met the inclusion criteria. Findings demonstrated that the PIC group had significantly improved OS (hazard ratio [HR]: 0.76 [0.66, 0.87]) and PFS (HR: 0.76 [0.66, 0.87]). The mOS (MD: 1.70 [1.51, 1.90] months) and mPFS (MD: 1.20 [0.61, 1.79] months) were also higher in the PIC group. OS and PFS advantages for the PIC group were confirmed across most subgroups. In the first two years of treatment, survival rates (OS and PFS) and extended duration of response in the PIC group increased over time. Both groups showed comparable total AEs, treatment-related AEs, ORR, and DCR. However, the PIC group had significantly higher rates of immune-related AEs (irAEs) and grade 3-5 irAEs.</p><p><strong>Conclusions: </strong>PIC is associated with improved OS and PFS in advanced BTC compared to chemotherapy alone, though the elevated risk of irAEs calls for careful monitoring.</p><p><strong>Trial registration: </strong>PROSPERO ID: CRD42024611835. PROSPERO link:  https://www.crd.york.ac.uk/PROSPERO/view/CRD42024611835 .</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"228"},"PeriodicalIF":2.5,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between PSCA gene polymorphism and hepatocellular carcinoma risk.","authors":"Xiechen Wang, Xiaoqiang Sun, Xuyin Wang, Yongqiang Wang, Hongmei Zhao, Jun Ma","doi":"10.1186/s12957-025-03878-z","DOIUrl":"10.1186/s12957-025-03878-z","url":null,"abstract":"<p><strong>Background: </strong>The current study aims to determine whether prostate stem cell antigen (PSCA) gene polymorphism confers a risk for hepatocellular carcinoma (HCC). The aim is to find out the novel markers for predicting HCC risk and provide an early warning mechanism for the population susceptible to HCC.</p><p><strong>Methods: </strong>A case-control study was used to select 160 HCC patients who were admitted to People's Hospital of Ningxia Hui Autonomous Region between May 2021 and April 2024 as the case group, and 280 healthy adults matching the gender and age of the case group were collected as the normal control group. PSCA gene polymorphism was detected using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). At the same time, whether the interaction of gene and smokers affects polymorphism is also investigated.</p><p><strong>Results: </strong>Significant associations were found at the rs2294008 and rs2976392 loci of PSCA gene (P < 0.05). However, there were no significant differences at the rs1045531 or rs2978974 loci (P > 0.05). All HCC patients were divided into smokers and non-smokers. The final results did not show any significant difference in genotype frequency between the two groups.</p><p><strong>Conclusion: </strong>The PSCA rs2294008 and rs2976392 polymorphisms contribute to an increased risk of HCC and serve as two novel markers for predicting HCC risk.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"229"},"PeriodicalIF":2.5,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and clinicopathological role of pretreatment fibrinogen-to-albumin ratio (FAR) in patients with gastric cancer: a meta-analysis.","authors":"Jiaying Wang, Zongxin Zhang, Ping Fei","doi":"10.1186/s12957-025-03885-0","DOIUrl":"10.1186/s12957-025-03885-0","url":null,"abstract":"<p><strong>Background: </strong>Fibrinogen-to-albumin ratio (FAR) has been previously suggested for its significance in forecasting gastric cancer (GC) prognosis, however, the results remained conflicting. The present work focused on clarifying FAR's accurate effect on forecasting GC prognosis via meta-analysis.</p><p><strong>Methods: </strong>This study thoroughly retrieved PubMed, Web of Science, Embase, Cochrane Library, and CNKI until January 4, 2025, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to forecast FAR's role in forecasting GC overall survival (OS) and disease-free survival (DFS).</p><p><strong>Results: </strong>We retrieved 12 studies recruiting 5665 cases in the present work. From the pooled findings, high FAR exhibited significant relation to unfavorable OS (HR = 1.68, 95%CI = 1.38-2.04, p < 0.001) of patients with GC. But FAR was not apparently linked with DFS of GC (HR = 1.24, 95%CI = 0.69-2.22, p = 0.468). According to our combined findings, elevated FAR exhibited significant connection to age ≥ 60 years (OR = 2.13, 95%CI = 1.72-2.65, p < 0.001), tumor size ≥ 5 cm (OR = 1.91, 95%CI = 1.13-3.24, p = 0.016), and TNM stage of III-IV (OR = 2.5, 95%CI = 2.08-3.23, p < 0.001). Nonetheless, FAR remained insignificantly linked with gender (OR = 1.16, 95%CI = 0.94-1.43, p = 0.162), invasion depth (OR = 2.01, 95%CI = 1.00-4.04, p = 0.050), N stage (OR = 1.30, 95%CI = 0.63-2.67, p = 0.482), tumor differentiation (OR = 1.22, 95%CI = 0.93-1.62, p = 0.153), and vascular invasion (OR = 1.11, 95%CI = 0.68-1.81, p = 0.687) of GC patients.</p><p><strong>Conclusion: </strong>In the present study, increased FAR dramatically predicted the dismal OS of GC. Moreover, high FAR showed obvious relation to older age, larger tumor size, and advanced stage of GC cases.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"227"},"PeriodicalIF":2.5,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the mortality trends of laryngeal cancer attributable to smoking worldwide from 1990 to 2021 and projections up to 2036.","authors":"Jie Yang, Xi-Shan Chen, Ying Lu","doi":"10.1186/s12957-025-03835-w","DOIUrl":"10.1186/s12957-025-03835-w","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to examine the global trends in the disease burden of laryngeal cancer (LC) attributable to smoking from 1990 to 2021, including mortality, and disability-adjusted life years (DALYs), and to predict trends for 2036.</p><p><strong>Methods: </strong>Data on LC attributable to smoking were obtained from the 2021 Global Burden of Disease (GBD) online database. Joinpoint regression analysis was used to calculate the average annual percent change (AAPC) to evaluate trends in LC attributable to smoking. Additionally, an Autoregressive Integrated Moving Average (ARIMA) model was applied to forecast future disease burden over the next 15 years.</p><p><strong>Results: </strong>From 1990 to 2021, the global age-standardized mortality rate (ASMR) of LC attributable to smoking decreased from 1.61 to 0.89 per 100,000 with an AAPC of -1.87%. The male mortality rate is significantly higher than that of females. In 2021, specific regions within the Balkans, the Middle East, and South Asia demonstrated notably higher compared to other global regions. According to the ARIMA model, the ASMR for LC attributable to smoking among males is projected to decline gradually from 2022 to 2036, while the decline in females is more gradual.</p><p><strong>Conclusion: </strong>From 1990 to 2021, the global mortality rate of LC attributable to smoking has declined, indicating a relative reduction in disease burden. However, the burden remains disproportionately higher among older adults, with males at a greater risk of mortality than females. Although the disease burden from LC attributable to smoking is expected to decline gradually over the next 15 years, it remains imperative to enhance smoking cessation efforts to further alleviate the disease burden.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"226"},"PeriodicalIF":2.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of short-term outcomes between multi-arm uniportal and multiport robotic-assisted thoracoscopic surgery based on propensity score matching.","authors":"Jun Chen, Yueying Yang, Yunfei Gao, Jianhu Chu, Zhaozhen Hou, Dongbo Luo","doi":"10.1186/s12957-025-03881-4","DOIUrl":"10.1186/s12957-025-03881-4","url":null,"abstract":"<p><strong>Objective: </strong>To compare the short-term outcomes of multi-arm uniportal robotic-assisted thoracoscopic surgery (URATS) and multiport robotic-assisted thoracoscopic surgery (MRATS) and to evaluate the safety and feasibility of URATS.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on clinical data from patients who underwent robotic-assisted thoracoscopic surgery in the Department of Thoracic Surgery II at Xinjiang Tumor Hospital between May 2023 and January 2025. Patients were categorized into the URATS and MRATS groups based on the surgical approach. A 1:1 propensity score matching (PSM) analysis was performed according to the clinical characteristics of the patients, and the short-term outcomes were compared between the two groups.</p><p><strong>Results: </strong>A total of 353 patients were included in this study, comprising 153 patients in the URATS group and 200 patients in the MRATS group. After PSM, each group consisted of 115 patients. The intraoperative blood loss in the URATS group was significantly lower than that in the MRATS group [median blood loss: 50 (30,100) mL vs. 100 (50,100) mL; P < 0.001]. The incidence of postoperative complications was lower in the URATS group compared to the MRATS group (5.2% vs. 10.4%, P = 0.041). The median duration of chest tube drainage was longer in the URATS group than in the MRATS group [4 (3,5) days vs. 3 (3,4) days, P = 0.003], and the median postoperative hospital stay was also slightly longer in the URATS group than in the MRATS group [5 (4,6) days vs. 4 (4,5) days, P = 0.037]. No significant differences were observed between the two groups in other perioperative parameters (P > 0.05).</p><p><strong>Conclusion: </strong>For pulmonary resection and mediastinal tumor resection, URATS demonstrates perioperative outcomes comparable to those of MRATS, with favorable safety and feasibility. URATS not only minimizes access-related surgical trauma but also results in a lower incidence of postoperative complications. Furthermore, it offers superior postoperative cosmetic outcomes, making it a promising technique for clinical application.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"224"},"PeriodicalIF":2.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PINK1 suppresses malignant phenotypes in esophageal squamous cell carcinoma.","authors":"Xiangyun Lu, Yuhui Pei, Hao Peng, Man Li, Jing Li, Yongkun Yao, Lianghai Wang","doi":"10.1186/s12957-025-03879-y","DOIUrl":"10.1186/s12957-025-03879-y","url":null,"abstract":"<p><strong>Objective: </strong>Esophageal squamous cell carcinoma (ESCC) is a common tumor characterized by a poor prognosis. PINK1 is strongly associated with tumorigenesis. However, the role of PINK1 in the progression of ESCC has not been elucidated.</p><p><strong>Methods: </strong>The expression levels of PINK1 in tumor samples and corresponding normal tissues were evaluated using RNA-sequencing and gene expression array datasets. Pathway enrichment and immune infiltration analyses were performed to explore the role of PINK1 in ESCC development. Subsequently, cell counting kit-8, colony-forming assay, and Transwell assays were implemented to measure the proliferation and motility of ESCC cells. The glucose, ATP, pyruvate, and lactate concentrations were measured using suitable assay kits.</p><p><strong>Results: </strong>PINK1 expression was significantly lower in ESCC samples across independent cohorts. In vitro assays demonstrated that PINK1 could inhibit the proliferation, migration, and invasive capabilities of ESCC cells. Furthermore, PINK1 could decrease intracellular glucose, lactic acid, pyruvic acid, and ATP levels in ESCC cells, whereas the glycolytic inhibitor 2-DG could abrogate its effect. Additionally, immunosuppressive-related gene sets were enriched in the PINK1 low-expression group. Immune infiltration analysis revealed that PINK1 expression was positively correlated with dendritic cells and T helper 1 cells within the tumor microenvironment.</p><p><strong>Conclusions: </strong>PINK1 inhibits cell growth, movement, glycolysis, and immune activation in ESCC, making it a promising therapeutic target.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"225"},"PeriodicalIF":2.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic changes in vasohibin and nitric oxide signaling following surgical resection of head and neck squamous cell carcinoma.","authors":"Ying-Hsuan Tai, Hsiang-Ling Wu, You-Hsiang Chu, Cheng-Hsien Wu, Shyh-Kuan Tai, Tso-Chou Lin, Shung-Tai Ho, Chih-Cherng Lu","doi":"10.1186/s12957-025-03853-8","DOIUrl":"10.1186/s12957-025-03853-8","url":null,"abstract":"<p><strong>Background: </strong>Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection.</p><p><strong>Methods: </strong>We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting.</p><p><strong>Results: </strong>Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL^-1 vs. 2425 ± 1493 pg·mL^-1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds.</p><p><strong>Conclusions: </strong>This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"221"},"PeriodicalIF":2.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of rectal malignant melanoma with long-term survival: case report and literature review.","authors":"Haitao Huang, Yanquan Liu, Hai Xiao, Jiachen Xie, Yiqun Kang, Ye Li, Huidong Guo","doi":"10.1186/s12957-025-03872-5","DOIUrl":"10.1186/s12957-025-03872-5","url":null,"abstract":"<p><strong>Background: </strong>Although cutaneous melanoma is relatively common, rectal malignant melanoma is extremely rare. Due to its rarity, rectal malignant melanoma is often not considered in the initial differential diagnosis. In such clinical scenarios, avoiding misdiagnosis, achieving early detection, and providing appropriate treatment remain major challenges and require particular attention. This case report presents a detailed account of the diagnostic and therapeutic process in a patient with primary rectal malignant melanoma. By sharing this case, we aim to provide clinicians with practical experience and valuable insights, thereby enhancing awareness and understanding of this rare condition within the medical community.</p><p><strong>Case presentation: </strong>A 56-year-old female presented to the hospital with a 10-day history of a perianal mass and hematochezia. Physical examination revealed a soft, flat abdomen with no palpable masses and normal bowel sounds. Imaging findings showed localized thickening of the distal rectum, diffuse mild thickening of the mid-to-upper rectal wall, and multiple small lymph nodes in the sigmoid mesocolon.Postoperative histopathological analysis, supported by immunohistochemical staining, confirmed the diagnosis of malignant melanoma. The patient underwent laparoscopic Miles surgery, followed by adjuvant abdominopelvic radiotherapy (GTVtb 50 Gy, CTV45 Gy) and targeted therapy with tislelizumab. She had an uneventful recovery and remained free of disease progression during 48 months of follow-up.</p><p><strong>Conclusions: </strong>This case of rectal malignant melanoma, incidentally diagnosed during hemorrhoidectomy, was successfully treated with laparoscopic Miles' procedure and targeted immunotherapy, resulting in long-term disease-free survival, thereby raising clinical awareness and providing valuable insights for managing similar cases.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"223"},"PeriodicalIF":2.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison among Early-Onset, Late-Onset, and Conventional-Onset Adenocarcinoma of Stomach and Esophagogastric Junction: a Retrospective Study.","authors":"Yidi Liang, Kai Liu, Valentin Kudriashov, Lifei Sun, Weihan Zhang, Xiaolong Chen, Linyong Zhao, Xiaohai Song, Kun Yang, Jiankun Hu","doi":"10.1186/s12957-025-03867-2","DOIUrl":"10.1186/s12957-025-03867-2","url":null,"abstract":"<p><strong>Background: </strong>The incidence of EOGC has been increasing, while COGC has decreased over the past few decades. The objective of this study was to identify differences in clinical characteristics and prognosis and to verify survival results among early-onset gastric cancer (EOGC), conventional-onset gastric cancer (COGC), late-onset gastric cancer (LOGC), and within the adenocarcinoma of the esophagogastric junction (AEG) group.</p><p><strong>Materials and methods: </strong>A retrospective trend analysis was conducted on patients diagnosed with gastric adenocarcinoma between 2002 and 2021. Additionally, 3,940 patients who underwent radical gastrectomy between January 2009 and December 2019 were included in a further analysis. The patients were categorized into three groups based on their age: EOGC, COGC, and LOGC. The study compared the three groups' demographic parameters, surgical details, pathological characteristics, and survival rates.</p><p><strong>Results: </strong>From 2002 to 2021, there was a fluctuating decrease in the surgical population of EOGC from 18.0% to 9.4% (p < 0.0001). 3940 patients were included in this analysis, EOGC (n = 572), COGC (n = 2816), and LOGC (n = 552). The EOGC group indicated a higher proportion of females (p < 0.0001), poorer differentiation p < 0.0001), higher proportion of signet-ring cell cancer (SRCC) (p < 0.0001), and lower Her-2 expression (p = 0.0038) than the COGC and LOGC groups. EOGC patients showed the best overall survival rate compared to COGC (p = 0.0110) and LOGC (p < 0.0001). After stratified by TNM stage, LOGC patients had the worst survival among all stages. When considering the patients with AEG, the EOGC group showed the worst survival outcome (p = 0.0130). Only patients with COGC showed improved survival with chemotherapy compared to those without it (stage II: p = 0.0051; stage III: p = 0.0160).</p><p><strong>Conclusion: </strong>A decreasing trend in the EOGC surgical population has been observed over the past 20 years at West China Hospital. Compared to COGC patients, EOGC patients had a higher proportion of females, SRCC cases, poorer differentiation, and lower Her-2 expression, but demonstrated a better survival outcome. Conversely, the worst prognosis outcome was observed in EOGC patients within the AEG subgroup. LOGC was an independent negative factor for survival results. Chemotherapy did not improve the prognosis for EOGC and LOGC patients at stage II and III.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"222"},"PeriodicalIF":2.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative computed tomography guided coil versus suture hook-wire localization for multiple pulmonary nodules.","authors":"Yue Dou, Hai-Hong Song, Yi-Bing Shi, Yong-Guang Gao, Sheng-Jie Bai","doi":"10.1186/s12957-025-03871-6","DOIUrl":"10.1186/s12957-025-03871-6","url":null,"abstract":"<p><strong>Background: </strong>Computed tomography (CT)-guided insertion of coil and suture hook-wire (SHW) insertion is commonly used for preoperative localization of multiple pulmonary nodules (PNs). However, the relative clinical efficacy and safety of these two methods have not been established. This study aimed to evaluate and compare the clinical performance and safety profiles of coil- and SHW-based localization techniques in patients with multiple PNs.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients with multiple PNs who underwent CT-guided coil or SHW localization followed by video-assisted thoracic surgery (VATS) resection between January 2020 and December 2024. Outcomes related to localization and VATS procedure parameters were compared.</p><p><strong>Results: </strong>A total of 35 patients (76 PNs) in the coil group and 37 patients (81 PNs) in the SHW group were retrospectively analyzed. Both groups achieved a 100% technical success rate for localization. The average time required for CT-guided localization was significantly shorter in the SHW group compared to the coil group (24.0 ± 12.3 min vs. 29.3 ± 9.0 min, P = 0.042). The incidence of pneumothorax was comparable between the 2 groups (25.7% for coil vs. 29.7% for SHW, P = 0.704). VATS-guided limited resection was successfully performed in all cases across both groups, with each patient undergoing complete one-stage resection of multiple PNs. The median VATS duration (130 min vs. 90 min, P = 0.084) and blood loss (25 ml vs. 50 ml, P = 0.152) were also similar in both groups.</p><p><strong>Conclusions: </strong>These findings indicate that both CT-guided coil and SHW localization techniques are safe and effective for the preoperative localization of multiple PNs. However, SHW localization provides a significant advantage by significantly shortening the procedure duration compared to the coil localization.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"219"},"PeriodicalIF":2.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}